Roxana Siles, MD, FAAAAI, staff in the Department of Allergy and Immunology at Cleveland Clinic and codirector of the Asthma Center at Cleveland Clinic, discusses the important need for chronic cough therapies and what issues with current treatments should be addressed by next-generation medications.
There is a great need for therapies that minimize the adverse reactions of currently available chronic cough treatments, especially for those who require daily therapy, emphasized Roxana Siles, MD, FAAAAI, staff in the Department of Allergy and Immunology at Cleveland Clinic and codirector of the Asthma Center at Cleveland Clinic.
Transcript
Given the challenges of a placebo effect, do you expect to see an FDA-approved therapy for chronic cough within the next few years?
I do, because I do think that there is a big need to address the patients who have refractory or unexplained cough; there’s good overlap between those 2 names. I definitely think that there’s a need, and certainly there was effectiveness that was shown [for gefapixant]. I think we do have to be careful of the adverse reactions, side effects, just like we do with any drug. But certainly, we do need a form of therapy that helps minimize the other side effects that we talked about, including the sedation and the other effects that we see with what we have available at this time.
Because most of these patients do cough every day, they do often require a daily form of therapy. And again, unfortunately, because a lot of these patients have a little bit of acid reflux, they might have asthma, it means not just 1 medication, and I think that’s the challenge, right? How do we stay on the regimen? Cost of medication is always something to think about also, and then again, minimizing the adverse reactions, which can occur with anything that we prescribe.
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Initiating BP Medication Linked to Higher Fall, Fracture Risks in Nursing Home Residents
May 2nd 2024Among over 60,000 nursing home residents who initiated antihypertensive medication, rates of excess fractures due to falls per 100 person-years were as high as 5 among certain patient groups, such as those with dementia and high blood pressure (BP).
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen